Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Summary

The purpose of this phase I trial is to evaluate the safety and feasibility of peposertib when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors, including pancreatic neuroendocrine tumors (PNETs).

General Information

NCT#: NCT04750954
Study ID: NCI-2021-00860
Trial Phase: Phase I

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: lutetium Lu 177 dotatate, Peposertib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search